Detrás de los titulares sobre el cáncer
Obtener más información sobre el programa de XRAY
Relevancia: Alta
Este artículo es de mayor interés para: Mujeres con mutaciones hereditarias en los genes BRCA1 o BRCA2
Estudio: Las mutaciones en el gen BRCA1 o BRCA2 pueden aumentar el riesgo de cáncer de endometrio
A Dutch study added further evidence that women with a BRCA1 mutation may have an elevated risk for endometrial cancer. The study found that the endometrial cancer in women with either a BRCA1 or BRCA2 mutation was more likely to be an aggressive form of cancer associated with a poor outcomes. (posted 11/30/21)
Este artículo está disponible en español.
Leer más ›
Relevancia: Media-alta
Este artículo es de mayor interés para: Personas con cáncer de próstata metastásico resistente a la castración
Estudio: Medicamentos para fortalecer los huesos: disminución del riesgo de fracturas causadas por los tratamientos contra el cáncer de próstata metastásico
Skeletal problems, especially bone fractures, are common in patients with advanced prostate cancer. To prevent these, many guidelines recommend the use of bone-protecting agents during treatment. The importance of giving a bone-protecting agent when treating patients with metastatic castration-resistant prostate cancer and bone metastases was confirmed in early results of an ongoing phase III trial. (11/5/21)
Este artículo está disponible en español.
Leer más ›
Relevancia: Alta
Este artículo es de mayor interés para: Personas con cáncer metastásico o recurrente
Estudio: Pruebas genéticas: recurso necesario para detectar mutaciones hereditarias en personas que padecen cáncer avanzado o metastásico
In a study of nearly 12,000 cancer patients with a variety of cancers, eight percent of participants with metastatic cancer had an inherited mutation in a cancer gene that qualified them for a targeted treatment approved by the FDA or for participation in a clinical trial. The majority of people with metastatic cancer were unaware that they had an inherited mutation, and had not receive gene-directed treatment to which their tumor may have responded. The study authors suggest that genetic testing for inherited mutations may be warranted for all patients with advanced or metastatic cancer. (posted 9/30/21)
Este artículo está disponible en español.
Leer más ›
Relevancia: Media-baja
Este artículo es de mayor interés para: Personas que consideren hacerse una biopsia líquida para detectar cáncer
Actualización: Biopsias líquidas para detectar, vigilar y tratar el cáncer
Could a simple blood test change cancer detection, treatment and monitoring? Several companies are offering a type of blood test known as a liquid biopsy to detect multiple cancers at their earliest stages, monitor response to treatment and help choose the best treatment. Although progress has been made using liquid biopsies to treat cancer, these tests have not yet been shown to detect cancer early enough to save lives. (posted 9/29/21)
Este artículo está disponible en español.
Leer más ›
Relevancia: Media
Este artículo es de mayor interés para: Personas sanas con un riesgo promedio de padecer cáncer colorrectal
Estudio: ¿Las bebidas azucaradas aumentan el riesgo de manifestación temprana del cáncer colorrectal?
A study of female nurses in the U.S. suggests that a high intake of sugar-sweetened beverages may increase the risk of colorectal cancer before age 50. However, researchers saw few early-onset colorectal cancer cases which limited the findings. (posted 9/21/21)
Este artículo está disponible en español.
Leer más ›
Relevancia: Media-alta
Este artículo es de mayor interés para: Personas transgénero
Artículo: La perspectiva de las personas transgénero tras ser diagnosticadas con cáncer relacionado con el género
An ABC News article provides viewpoints and data that conveys the added stress experienced by transgender and gender-nonconforming people when they are diagnosed with gender-associated cancer (e.g., ovarian or prostate cancer) that does not match their gender identity. (posted 9/13/21)
Este artículo está disponible en español.
Leer más ›
Relevancia: Media-alta
Este artículo es de mayor interés para: Personas con cáncer de mama triple negativo de alto riesgo en etapa inicial
Actualización: Pembrolizumab recibe la aprobación de la FDA para pacientes con cáncer de mama triple negativo en etapa inicial
The FDA approved the immunotherapy drug pembrolizumab (Keytruda) for the treatment of early-stage triple-negative breast cancer that has a high risk for recurrence. This marks the first approval for this type of drug, known as an immune checkpoint inhibitor, for the treatment of early-stage breast cancer. (posted 9/2/21)
Este artículo está disponible en español.
Leer más ›
Relevancia: Alta
Este artículo es de mayor interés para: Mujeres con cáncer de mama que consumen café o té.
Estudio: El consumo de café o té puede prolongar la vida después de padecer cáncer de mama
In a study of 8,900 women with stage 1, 2 or 3 breast cancer, those who drank coffee survived longer after a breast cancer diagnosis than those who did not drink coffee. Both coffee and tea were linked to improved survival from any cause. Several factors were linked to greater coffee or tea consumption, so this finding must be taken with some caution. However, breast cancer survivors who are regular coffee or tea drinkers may find this research reassuring. (posted 8/31/21)
Este artículo está disponible en español.
Leer más ›
Relevancia: Alta
Este artículo es de mayor interés para: Mujeres blancas y negras no hispanas con cáncer de mama
Estudio: La frecuencia de las mutaciones hereditarias relacionadas con el cáncer de mama es similar en mujeres blancas y negras
The CARRIERS study looked at the rate of inherited mutations in women with and without breast cancer. In an extension of the CARRIERS study, researchers found no difference in the frequency of inherited mutations in breast cancer genes among Black and white women with breast cancer. A few individual genes differed in frequency: BRCA2 and PALB2 mutations were seen more often in Black women, while CHEK2 mutations were seen less often. Researchers concluded that race should not be used to determine who is referred for genetic testing. (posted 8/13/21)
Este artículo está disponible en español.
Leer más ›
Relevancia: Media-alta
Este artículo es de mayor interés para: Personas con cáncer de mama HER2- en etapa inicial y una mutación hereditaria en los genes BRCA.
Directrices: Las directrices de la ASCO recomiendan olaparib para personas con cáncer de mama en etapa inicial con alto riesgo de recurrencia y una mutación hereditaria en los genes BRCA
The American Society of Clinical Oncology (ASCO) has updated their breast cancer treatment guidelines to include treatment with the PARP inhibitor olaparib (Lynparza) for one year after completing chemotherapy, surgery and radiation (if used) to improve outcomes of people with an inherited mutation in BRCA1 or BRCA2 with early-stage, HER2-negative breast cancer who have a high risk for recurrence. (posted 8/6/21) Update: Based on results from the OlympiA Study, the FDA approved olaparib as adjuvant treatment for people with an inherited BRCA mutation who have been diagnosed with early-stage HER2-negative breast cancer and are at high risk for recurrence. (03/11/2022)
Este artículo está disponible en español.
Leer más ›